Abstract
Several studies have identified blood proteins that influence brain aging performance in mice, yet translating these findings to humans remains challenging. Here we found that higher predicted plasma levels of Tissue Inhibitor of Metalloproteinases 2 (TIMP2) were significantly associated with improved global cognition and memory performance in humans. We first identified 12 proteins with aging or rejuvenating effects on murine brains through a systematic review. Using protein quantitative trait loci data for these proteins, we computed polygenic scores as proxies for plasma protein levels and validated their prediction accuracy in two independent cohorts. Association models between genetic proxies and cognitive performance highlighted the significance of TIMP2, also when the models were stratified by sex, APOE-ε4, and Aβ42 status. This finding aligns with TIMP2’s brain-rejuvenating role in murine models, suggesting it as a promising therapeutic target for brain aging and age-related brain diseases in humans.
Competing Interest Statement
CC has received research support from: GSK and EISAI. CC is a member of the scientific advisory board of Circular Genomics and owns stocks. CC is a member of the scientific advisory board of ADmit. MS-C has given lectures in symposia sponsored by Almirall, Eli Lilly, Novo Nordisk, Roche Diagnostics, and Roche Farma; received consultancy fees (paid to the institution) from Roche Diagnostics; and served on advisory boards of Roche Diagnostics and Grifols. He was granted a project and is a site investigator of a clinical trial (funded to the institution) by Roche Diagnostics. In-kind support for research (to the institution) was received from ADx Neurosciences, Alamar Biosciences, Avid Radiopharmaceuticals, Eli Lilly, Fujirebio, Janssen Research & Development, and Roche Diagnostics. The remaining co-authors have no conflicts to disclose.
Funding Statement
The research leading to these results has received funding from la Caixa Foundation ID 100010434 under agreement LCFPRGN1750300004, the Health Department of the Catalan Government Health Research and Innovation Strategic Plan PERIS 2016-2020 grant SLT0021600201 and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project TriBEKa-17-519007. Additional support has been received from the Universities and Research Secretariat Ministry of Business and Knowledge of the Catalan Government under grant no 2021 SGR 00913 and 2021 SGR 01137. FA receives funding from the JDC2022-049347-I grant funded by the MCIUAEI1013039501100033 and the European Union NextGenerationEU/PRTR. This work was supported in part by grants from the National Institutes of Health R01AG044546 CC P01AG003991 CC JCM RF1AG053303 CC RF1AG058501 CC U01AG058922 CC, the Chan Zuckerberg Initiative CZI the Alzheimer's Association Zenith Fellows Award ZEN-22-848604 awarded to CC, and an Anonymous foundation. The recruitment and clinical characterization of research participants at Washington University were supported by NIH P30AG066444 JCM P01AG03991 JCM and P01AG026276 JCM. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders the Neurogenomics and Informatics Center NGI httpsneurogenomicswustledu and the Departments of Neurology and Psychiatry at Washington University School of Medicine. MS-C receives funding from the European Research Council ERC under the European Union's Horizon 2020 research and innovation programme Grant agreement No 948677 ERA PerMed ERAPERMED2021-184 Project PI1900155 and PI2200456 funded by Instituto de Salud Carlos III ISCIII and co-funded by the European Union and from a fellowship from la Caixa Foundation ID 100010434 and from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 847648 LCFBQPR2111840004. NV-T was supported by the Spanish Ministry of Science and Innovation - State Research Agency IJC2020-043216-IMCINAEI101303950110033 and the European Union NextGenerationEU/PRTR and currently receives funding from the Spanish Research Agency MICIUAEI101303950110033 grant RYC2022-038136-I cofunded by the European Union FSE+ and grant PID2022-143106OA-I00 cofunded by the European Union FEDER. Additionally NV-T is supported in part by the William H Gates Sr Fellowship from the Alzheimer's Disease Data Initiative. All CRG authors acknowledge the support of the Spanish Ministry of Science Innovation and Universities to the EMBL partnership the Centro de Excelencia Severo Ochoa and the CERCA ProgrammeGeneralitat de Catalunya.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ALFA study was conducted in accordance with the directives of the Spanish Law 14 2007 of July 3 on Biomedical Research Ley 142007 de Investigacion Biomedica. The ALFA study protocol was approved by the Independent Ethics Committee Parc de Salut Mar Barcelona and registered at Clinicaltrials.gov, Identifier NCT02485730. All participants accepted the study procedures by signing the study's informed consent form that had also been approved by the same Institutional Review Board. The ethics committee and institutional review board of Washington University in St. Louis School of Medicine approved this study. All participants provided informed consent for all data used in the present study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
